Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.

British journal of haematology - 1 May 2008

Braun Thorsten, Fenaux Pierre

Abstract excerpt

Novel strategies are required for treatment of acute myeloid leukaemia (AML) and higher risk myelodysplastic syndrome (MDS) patients who are not eligible for intensive chemotherapy and/or allogenic stem cell transplantation. As activating RAS mutations are frequent in these diseases, one novel approach, consisting of interfering with isoprenylation of RAS proteins by farnesyltransferase inhibitors (FTIs), has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Farnesyltranstransferase

Share to Genes, ras

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Source

Identifiers

PMID: 18410457
DOI: 10.1111/j.1365-2141.2008.07099.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.PMID 18410457Read ↗

Role of farnesyltransferase inhibitors in hematologic malignancies.Semantic proximity Read ↗

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemiaSemantic proximity Read ↗

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Semantic proximity Read ↗

Evolving therapies: farnesyltransferase inhibitors.Semantic proximity Read ↗

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.Semantic proximity Read ↗

Farnesyltransferase inhibitors: potential role in the treatment of cancer.Semantic proximity Read ↗

Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.Semantic proximity Read ↗

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcomaSemantic proximity Read ↗

Inhibition of farnesyltransferase activity diminishes hematopoietic stem cell <i>ex vivo</i> expansion abilitySemantic proximity Read ↗

Perspectives on farnesyl transferase inhibitors in cancer therapySemantic proximity Read ↗

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.Semantic proximity Read ↗

Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.